Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in advanced HER2-positive solid tumors
NCT02881138Phase 1Completed
- Sponsor
- RemeGen
- Start
- Mar 2016
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of disitamab vedotin in solid tumor, sponsored by RemeGen. Primary endpoints: Maximal Tolerance Dose at 28 days and Adverse Events at 2 years. Started Mar 2016; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02881138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881138.